Christina Bazan
Family · Willow Park, TXNPI 1851995682
Payments from drug & device makers
Across 114 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$764
- Novo Nordisk$358
- Corcept Therapeutics$345
- Bayer$256
- Teva Pharmaceuticals USA, Inc.$234
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$232
- plus $997 from 20 others
What the payments were for
- Food & beverage$3,187100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $764 |
| Novo Nordisk | 10 | $358 |
| Corcept Therapeutics | 8 | $345 |
| Bayer | 10 | $256 |
| Teva Pharmaceuticals USA, Inc. | 2 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $232 |
| Boehringer Ingelheim | 4 | $229 |
| AbbVie | 5 | $202 |
| Lilly USA, LLC | 9 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Amgen | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Exact Sciences | 2 | $32 |
| Tactile Systems Technology Inc | 2 | $30 |
| Optinose US, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Scynexis, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$230
- Korlym$223
- UBRELVY$129
- Ozempic$125
- ProAir Digihaler$122
- ArmonAir Digihaler$122
- AirDuo RespiClick$122
- FARXIGA$121
- Kerendia$116
- JARDIANCE$114
- AUSTEDO$112
- XIFAXAN$103
How this compares
$3,187 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $87,865 |
| OzempicSemaglutide | 39 | $54,743 |
| TrulicityDulaglutide | 13 | $30,023 |
| FarxigaDapagliflozin Propanediol | 14 | $24,769 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,790 |
| Bupropion XlBupropion Hcl | 22 | $4,343 |
| Atorvastatin Calcium | 296 | $2,997 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,661 |
| Levothyroxine Sodium | 150 | $1,585 |
| Gabapentin | 74 | $1,542 |
| Amlodipine Besylate | 214 | $1,372 |
| Omeprazole | 70 | $1,262 |
| Ezetimibe | 32 | $920 |
| Lisinopril | 143 | $888 |
| SynthroidLevothyroxine Sodium | 12 | $878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $229 | $87,86559 claims |
| Novo NordiskOzempic | $358 | $54,74339 claims |
| Lilly USA, LLCTrulicity | $156 | $30,02313 claims |
| AstraZenecaFarxiga, Symbicort | $764 | $29,55933 claims |
| AbbVieSynthroid | $202 | $87812 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $14 | $60826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Willow Park
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.